Reuters -- Disappointing clinical results sent shares in Danish biotechnology company Genmab tumbling 26 percent on Tuesday as investors questioned sales prospects for its key drug Arzerra in treating blood cancer.
Reuters -- Disappointing clinical results sent shares in Danish biotechnology company Genmab tumbling 26 percent on Tuesday as investors questioned sales prospects for its key drug Arzerra in treating blood cancer.
